Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Thierer

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The American Journal of Cardiology|March 30, 2010
Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study)Jorge Thierer, Adriana Acosta, Nora Vainstein, et al.
Journal of Cardiothoracic and Vascular Anesthesia|November 2, 2010
Immediate extubation after off-pump coronary artery bypass graft surgery in 1,196 consecutive patients: feasibility, safety and predictors of when not to attempt itAlberto G Dorsa, Adriana I Rossi, Jorge Thierer, et al.
The American Journal of Cardiology|January 31, 2007
Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR)Fernando A Cura, Alejandro Garcia Escudero, Daniel Berrocal, et al.
JACC. Heart Failure|May 25, 2023
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Jorge Thierer, Brian L Claggett, et al.
European Journal of Heart Failure|September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
JACC. Heart Failure|March 4, 2022
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER TrialScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
The New England Journal of Medicine|August 26, 2022
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D Solomon, John J V McMurray, Brian Claggett, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The American Journal of Cardiology|March 30, 2010
Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study)Jorge Thierer, Adriana Acosta, Nora Vainstein, et al.
Journal of Cardiothoracic and Vascular Anesthesia|November 2, 2010
Immediate extubation after off-pump coronary artery bypass graft surgery in 1,196 consecutive patients: feasibility, safety and predictors of when not to attempt itAlberto G Dorsa, Adriana I Rossi, Jorge Thierer, et al.
The American Journal of Cardiology|January 31, 2007
Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR)Fernando A Cura, Alejandro Garcia Escudero, Daniel Berrocal, et al.
JACC. Heart Failure|May 25, 2023
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Jorge Thierer, Brian L Claggett, et al.
European Journal of Heart Failure|September 2, 2022
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
JACC. Heart Failure|March 4, 2022
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER TrialScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
The New England Journal of Medicine|August 26, 2022
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D Solomon, John J V McMurray, Brian Claggett, et al.
Pageof 3